retatrutide mechanism gip glp-1 glucagon triple agonist Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data The Road towards Triple Agonists:

The study also reflects that those taking the medications for weight loss only are significantly more interested in products that offer key nutrients such as: Fortified with vitamins and nutrients (75%) High protein or protein fortified (74%) Gut health support (73%) For those no longer taking the medication, 76% report eating the same amount or less food

Managing Side Effects Like any medication, GLP-1 therapy can cause side effects

PMID: 40427605

Ethics declarations Ethics approval and consent to participate The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Independent Institutional Ethics Committee of IRCCS MultiMedica, Milan (protocol code 24/2012(153))